Rapid pathogen identification and phenotypic antimicrobial susceptibility directly from urine specimens.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 11 2022
Historique:
received: 22 07 2022
accepted: 19 10 2022
entrez: 15 11 2022
pubmed: 16 11 2022
medline: 19 11 2022
Statut: epublish

Résumé

Implementing effective antimicrobial therapy close to the onset of infection lowers morbidity and mortality and attenuates the spread of antimicrobial resistance. Current antimicrobial susceptibility testing (AST) methods, however, require several days to determine optimal therapies. We present technology and an automated platform that identify (ID) Urinary Tract Infection pathogens in 45 min and provide phenotypic AST results in less than 5 h from urine specimens without colony isolation. The ID and AST tests count cells fluorescently labeled with specific rRNA probes using non-magnified digital imaging. The ID test detected five pathogens at ≤ 7,000 CFU/mL and had a linear range of ~ 4 orders of magnitude. For contrived specimens, AST tests gave 93.1% categorical agreement with 1.3% Very Major Errors (VME), 0.3% Major Errors (ME), and 6.3% minor Errors (mE) compared to the broth microdilution (BMD) reference method. For clinical specimens, the ID test had 98.6% agreement and the AST test had 92.3% categorical agreement with 4.2% mE, 3.4% ME and 4.0% VME compared to BMD. Data presented demonstrates that direct-from-specimen AST tests can accurately determine antimicrobial susceptibility/resistance for each pathogen in a specimen containing two pathogens. The method is robust to urine matrix effects and off-target commensal and contaminating bacteria.

Identifiants

pubmed: 36380053
doi: 10.1038/s41598-022-22792-y
pii: 10.1038/s41598-022-22792-y
pmc: PMC9666529
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

18315

Subventions

Organisme : NIAID NIH HHS
ID : R44 AI157672
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : 1R01AI117058-01
Organisme : U.S. Department of Health & Human Services | Biomedical Advanced Research and Development Authority (BARDA)
ID : #HHSO100201500022C
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : >1R44AI157672-01

Informations de copyright

© 2022. The Author(s).

Références

Nat Rev Microbiol. 2015 May;13(5):269-84
pubmed: 25853778
Sci Rep. 2018 May 30;8(1):8364
pubmed: 29849171
Clin Microbiol Infect. 2017 Jan;23(1):2-22
pubmed: 27890457
Infect Control Hosp Epidemiol. 2016 Nov;37(11):1288-1301
pubmed: 27573805
Lancet Infect Dis. 2012 Dec;12(12):919-24
pubmed: 23103175
Int Urol Nephrol. 2020 Mar;52(3):431-436
pubmed: 31691136
PLoS One. 2022 Feb 16;17(2):e0263868
pubmed: 35171945
BJOG. 2020 Jan;127(2):193-201
pubmed: 31469215
Antibiotics (Basel). 2021 Feb 20;10(2):
pubmed: 33672677
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Antibiotics (Basel). 2022 Mar 23;11(4):
pubmed: 35453179
Nat Rev Microbiol. 2020 May;18(5):299-311
pubmed: 32055026
Adv Sci (Weinh). 2021 Feb 01;8(6):2003419
pubmed: 33747737
Eur Urol Focus. 2019 Jan;5(1):5-9
pubmed: 30448051
Nat Rev Urol. 2017 May;14(5):296-310
pubmed: 28248946
Clin Infect Dis. 2022 Apr 9;74(7):1284-1292
pubmed: 34463708
Clin Lab Med. 2019 Sep;39(3):333-344
pubmed: 31383260

Auteurs

Larry Burg (L)

First Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA. larry@firstlightdx.com.

Gretel Crewe (G)

First Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.

James DiMeo (J)

First Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.

Xin Guo (X)

First Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.

Carmen G Li (CG)

First Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.

Melissa Mayol (M)

First Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.

Andrew Tempesta (A)

First Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.

William Lauzier (W)

First Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.

Rachelle Markham (R)

First Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.

Katarzyna Crissy (K)

First Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.

Colleen Barry (C)

First Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.

Bruce Walsh (B)

First Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.

James E Kirby (JE)

Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 02215, USA.

Don Straus (D)

First Light Diagnostics, 2 Omni Way, Chelmsford, MA, 01824, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH